MBRX

Announcements

Nothing here yet

Daily updates

• Moleculin Biotech published peer-reviewed pooled cardiac safety data for Annamycin across five clinical studies involving 90 AML and metastatic soft tissue sarcoma patients, showing no clinical or subclinical cardiotoxicity despite cumulative doses above traditional anthracycline thresholds.Sep 28, 2026

FDA designations

Nothing here yet

News

• Moleculin announces publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular MedicineSep 28, 2026
• New preclinical data presented at AACR show Annamycin can turn immunologically cold pancreatic tumors hotSep 26, 2026
• Moleculin Biotech secures a Mexican patent protecting its lung-targeted liposomal annamycin through 2040Sep 23, 2026
• Moleculin reported positive interim results from the MIRACLE Phase 2/3 trial, with a 37% blinded CRc rate in venetoclax-failed relapsed/refractory AML patientsJul 31, 2026
• Moleculin reported positive interim Phase 2/3 MIRACLE results with higher complete remission rates for AnnamycinJul 1, 2026